VVOS Q4 2025 Earnings Call Summary

Full Year 2025 Revenue: Increased by $2.4 million (16%) to approximately $17 million, driven by a $4.8 million rise in sleep testing services and $2.2 million from treatment revenue at the Sleep Center of Nevada (SCN).
Product Revenue Decline: Legacy product sales dropped by $1.4 million, with a total of 25,441 oral appliances sold, reflecting an 18% decrease in revenue from 2024.
Gross Profit: Rose to $10.5 million (17% increase), maintaining a gross margin of 60%.
Operating Expenses: Increased significantly to $30.4 million from $20.2 million, primarily due to higher general and administrative costs associated with SCN operations.
Net Loss: Widened to $21.2 million, with $1.4 million attributed to one-time costs.
Cash Position: As of December 31, 2025, cash and cash equivalents stood at approximately $2 million, with total liabilities rising to $26.7 million due to debt incurred for the SCN acquisition.

Acquisition of SCN: The integration of the Sleep Center of Nevada is progressing well, with positive endorsements from medical specialists and the establishment of in-network insurance coverage.
New Business Model: Transitioning to a medical provider-focused strategy, reducing reliance on legacy VIP dentist enrollments.
Sleep Optimization (SO) Teams: Deployment of specialized teams to enhance patient education and treatment access, with plans for expansion in 2026.
Market Expansion: Continued efforts to establish partnerships with medical specialty groups and expand diagnostic and treatment services, including a pediatric OSA program.

Revenue Growth Expectations: Anticipation of increased revenue from higher-priced products and expanded treatment options in 2026, with a goal of achieving cash flow positive operations by year-end 2026.
Operational Enhancements: Plans to address staffing and insurance credentialing challenges to improve patient access and operational efficiency.

Q4 Revenue Decline: Revenue dropped to $3.8 million in Q4 from $6.8 million in Q3, attributed to provider absences and insufficient staffing.
Increased Operating Losses: The strategic transition has led to higher operating costs, impacting profitability.
Staffing Challenges: Provider turnover and recruitment issues in Q4 affected service delivery and revenue generation, although measures are being taken to mitigate this in the future.

Q4 Revenue Drop Explanation: CEO Kirk Huntsman noted that the decline was due to unexpected provider absences, which have since been addressed with new hires.
Q1 Expectations: Anticipated improvement in Q1 performance, with a more significant impact expected in Q2 as new providers become fully operational.
Long-term Financial Goals: CFO Bradford Amman indicated that to achieve cash flow positivity, the company would need to nearly double its revenue run rate by 2027.
Insurance Participation: Recent in-network agreements with payers are expected to positively influence revenue streams moving forward.

Overall, Vivos is optimistic about its strategic pivot and the potential for future growth, despite facing challenges in the transition period.

VVOS — Vivos Therapeutics, Inc.